HK inno.N
innovate New & Next inno.N is making the leap towards becoming the next global bio healthcare company
HK이노엔
바이오헬스기업 HK이노엔. 케이캡, 컨디션, 비원츠 등 전문의약품 및 헬스, 뷰티, 음료 제품 소개, 연구소개, ESG 등 정보 제공.
HK inno.N (KOSDAQ:195940) Company Profile & Description
3 天之前 · Company profile for HK inno.N Corporation (KOSDAQ:195940) with a description, list of executives, contact details and other key facts.
HK inno.N Corporation (195940.KQ) - Yahoo Finance
Find the latest HK inno.N Corporation (195940.KQ) stock quote, history, news and other vital information to help you with your stock trading and investing.
195940 Stock Price | HK Inno.N Corp. Stock Quote (S. Korea: KRX ...
2 天之前 · HK inno.N Corp. engages in the provision of healthcare services. It offers EPOKINE, LEUKOKINE, and CALMTOP. The company was founded in 1984 and is headquartered in Seoul, South Korea. 195940...
HK inno.N moves topical JAK inhibitor into phase 2 for atopic ...
2025年3月17日 · HK inno.N has secured approval from the Ministry of Food and Drug Safety for a phase 2 trial of IN-115314, a topical janus kinases (JAK-1) inhibitor targeting mild to moderate atopic dermatitis.Unlike oral JAK inhibitors, IN-115314 is designed for direct application to inflamed skin, limiting system
先为达生物与HK inno.N Corporation宣布就伊诺格鲁肽注射液的 …
2024年5月7日 · 伊诺格鲁肽注射液是一种具有cAMP偏向性的新型长效GLP-1激动剂，可用于治疗2型糖尿病、肥胖症和代谢功能障碍相关的脂肪性肝炎（MASH）。 根据协议，先为达生物将获得首付款， 并将有资格获得高达5600万美元的研发、注册和商业化相关的里程碑付款，以及产品商业化后高达两位数字的销售额提成。 HK inno.N Corporation将获得在韩国开发和商业化伊诺格鲁肽注射液的独家权益。 先为达生物仍将保留在全球所有其他市场开发和商业化伊诺格鲁肽注射 …
HK inno-n - LinkedIn
Since its establishment in 1984, HK inno.N has gained competitiveness in the businesses of prescription drugs, active pharmaceutical ingredients, health supplements and beauty products.
HK Inno.N Corp. (195940) Stock Price Today - WSJ
View the latest HK Inno.N Corp. (195940) stock price, news, historical charts, analyst ratings and financial information from WSJ.
HK inno.N
inno.N is targeting the global pharmaceutical&bio market beyond Korea with its portfolio of various chronic disease drugs. We are developing and supplying excellent drugs that improve the quality of life based on the potential that has been grown through blockbusters by developing K-CAB, Korea's 30th new drug, for the treatment of ...